Hemenway Trust Co LLC Acquires 2,398 Shares of Johnson & Johnson (JNJ)

Hemenway Trust Co LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,000 shares of the company’s stock after acquiring an additional 2,398 shares during the quarter. Johnson & Johnson comprises approximately 3.3% of Hemenway Trust Co LLC’s portfolio, making the stock its 5th biggest holding. Hemenway Trust Co LLC’s holdings in Johnson & Johnson were worth $15,991,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of JNJ. New England Asset Management Inc. raised its holdings in Johnson & Johnson by 15.2% during the 1st quarter. New England Asset Management Inc. now owns 25,632 shares of the company’s stock valued at $3,193,000 after acquiring an additional 3,382 shares during the period. Investment Centers of America Inc. raised its holdings in Johnson & Johnson by 5.5% during the 1st quarter. Investment Centers of America Inc. now owns 109,264 shares of the company’s stock valued at $13,574,000 after acquiring an additional 5,727 shares during the period. Stellar Capital Management LLC raised its holdings in Johnson & Johnson by 0.4% during the 1st quarter. Stellar Capital Management LLC now owns 27,603 shares of the company’s stock valued at $3,438,000 after acquiring an additional 110 shares during the period. Harbour Capital Advisors LLC raised its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Harbour Capital Advisors LLC now owns 18,629 shares of the company’s stock valued at $2,320,000 after acquiring an additional 101 shares during the period. Finally, Hutchens Investment Management Inc purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at $204,000. 65.70% of the stock is currently owned by institutional investors and hedge funds.

JNJ has been the subject of a number of recent analyst reports. Goldman Sachs Group lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price target for the company from $125.00 to $130.00 in a research report on Wednesday, September 20th. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target for the company in a research report on Monday, October 30th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company an “outperform” rating in a research report on Thursday, October 19th. BMO Capital Markets boosted their price target on shares of Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $145.52.

Johnson & Johnson (JNJ) opened at $141.89 on Tuesday. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $144.35. The stock has a market cap of $381,190.00, a price-to-earnings ratio of 24.63, a P/E/G ratio of 2.67 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. During the same period in the previous year, the business earned $1.68 earnings per share. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be given a $0.84 dividend. The ex-dividend date is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.37%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

TRADEMARK VIOLATION WARNING: “Hemenway Trust Co LLC Acquires 2,398 Shares of Johnson & Johnson (JNJ)” was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2018/01/09/hemenway-trust-co-llc-acquires-2398-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit